FIELD: medicine; immunology; cellular biotechnology.
SUBSTANCE: invention relates in particular to a method for enhancing antitumor T-cell immunity in lung cancer.
EFFECT: invention makes it possible to suppress the growth of a lung tumour by increasing specific cytotoxicity and resistance to the action of CD8+ T-lymphocyte tumour cells induced by metabolic reprogramming.
1 cl, 3 dwg, 6 tbl, 2 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD AND COMPOSITIONS FOR CELLULAR IMMUNOTHERAPY | 2012 |
|
RU2688185C2 |
COMPOSITIONS AND METHODS OF TREATING INFECTIONS AND TUMOURS | 2007 |
|
RU2540490C2 |
METHOD AND COMPOSITIONS FOR CELL IMMUNOTHERAPY | 2013 |
|
RU2700765C2 |
CDCA1 PEPTIDE AND PHARMACEUTICAL DRUG CONTAINING IT | 2008 |
|
RU2486195C2 |
COMPOSITIONS AND METHODS OF TREATING INFECTIONS AND TUMOURS | 2007 |
|
RU2478400C2 |
METHOD OF TREATING ONCOLOGICAL DISEASES | 2010 |
|
RU2489169C2 |
METHOD FOR ENHANCING THE GROWTH OF B16/F10 MELANOMA VERSUS THE GROWTH OF B16/F10 MELANOMA WITH SELF-GRAFTING AND SLOWING THE GROWTH OF LLC (LEWIS CARCINOMA) VERSUS THE GROWTH OF LLC WITH SELF-GRAFTING IN CASE OF MULTIPLE PRIMARY MALIGNANT TUMORS AGAINST THE BACKGROUND OF PRIMARY IMMUNODEFICIENCY | 2021 |
|
RU2759487C1 |
PARTICLES PM21 FOR IMPROVEMENT OF HOMING OF NK-CELLS IN BONE MARROW | 2018 |
|
RU2777993C2 |
DEVICES AND METHODS FOR SELECTION OF CELLS RESISTANT TO APOPTOTIC SIGNALS AND THEIR APPLICATIONS | 2013 |
|
RU2630301C2 |
IMMUNE CELLS DEFECTIVE BY Suv39h1 | 2018 |
|
RU2784531C2 |
Authors
Dates
2023-04-07—Published
2022-06-06—Filed